Lv51
1400 积分 2023-05-19 加入
Strategies to Address Chimeric Antigen Receptor Tonic Signaling
8小时前
已完结
Targeting ECM-producing cells with CAR-T therapy alleviates fibrosis in chronic kidney disease
12小时前
已完结
A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles
21天前
已完结
A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles
23天前
已完结
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
26天前
已完结
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
26天前
已完结
Tislelizumab augment the efficacy of CD19/22 dual‐targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B‐cell non‐Hodgkin lymphoma
30天前
已完结
CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study
30天前
已完结
CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit
1个月前
已完结
Prolonged but finite antigen presentation promotes reversible defects of “helpless” memory CD8+ T cells
1个月前
已完结
皖公网安备34019202002308
